Ventorino_Jenna

Jenna Ventorino

Jenna Ventorino is a corporate lawyer who provides ongoing counsel to public and private life sciences and technology companies throughout their lifecycle. She advises clients in the biotechnology, medical technology and software industries in complex transactions including intellectual property licensing, private securities offerings and various exit transactions. She draws on her prior experience as in-house counsel to help her clients navigate their legal and business challenges.

In addition to advising clients on a wide range of corporate and securities matters, Ms. Ventorino advises clients on various IP-related transactions including technology acquisitions and divestitures, development arrangements, strategic alliances and other collaboration agreements. As well as advising clients on strategic transactions, Ms. Ventorino regularly counsels clients regarding general and complex corporate matters, including venture capital and other financings. 

Professional Activities

Ms. Ventorino is an active member of WilmerHale's Women's Leadership Initiative and leads the east coast's Female Founders initiative—an effort that brings awareness to the issues facing leaders and executives from women-led startup businesses.

Additionally, she is a member of the Boston Bar Association, Women's Bar Association, the Cornell University Alumni Ambassador Association, and is an alumni mentor for the Boston University School of Law. She is a former board member of the Cornell University Human Ecology Alumni Association.

Past Experience

Prior to joining the firm, Ms. Ventorino worked as an associate at a business law firm where she negotiated VC financings, mergers, acquisitions, divestitures and other strategic transactions, and advised on IP-centered strategic transactions and joint ventures.

Ms. Ventorino previously worked as an attorney for Kenexa Technology, Inc. (formerly Salary.com, Inc.), where she managed the compensation division.

Experience

  • Collaborations and Licensing Transactions

    • Editas Medicine in its strategic alliance and option agreement with Allergan;
    • MacroGenics in its collaboration with I-Mab;
    • Spark Therapeutics in its synthetic vaccine particles licensing transaction with Selecta Biosciences, and in its licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational Luxturna outside the United States; and
    • Voyager Therapeutics in its restructured gene therapy relationship with Sanofi Genzyme, and various collaboration agreements with Neurocrine Biosciences and AbbVie.
  • Corporate Transactions

    • Aileron Therapeutics, Inc. in its initial public offering;
    • a global institutional investor in its preferred stock financings of ZipRecruiter and ezCater;
    • Hydra Biosciences in its sale of its lead pre-clinical pain program to Eli Lilly;
    • numerous companies in venture capital and private financings, including Aileron Therapeutics, Altiostar Networks, Accent Therapeutics, Daktari Diagnostics, Disarm Therapeutics, Jebbit, Nantero and RightHand Robotics; and
    • venture capital firms including MPM Capital, Samsara BioCapital and Spark Capital in various private placement financings and strategic investments.

Recognition

  • Named a 2017 and 2018 Massachusetts Rising Star by Super Lawyers for her business/corporate and technology transactions practices
  • Selected to participate in the 2015-2016 Women's Bar Association Women's Leadership Initiative

Insights & News

Credentials

  • Education

    • JD, Boston University School of Law, 2008

      cum laude Editor, American Journal of Law and Medicine
    • MS, Nutrition and Exercise Science, Queens College, City University of New York, 2004

      Sigma Xi National Scientific Research Society
    • BS, Nutritional Science, Cornell University, 1999

      Phi Eta Sigma National Honor Society
  • Admissions

    • Massachusetts

    • New York

Credentials